Restricted accessResearch articleFirst published online 2018-9
Translation of clinical trial data to changes in clinical practice: rapid transition from tenofovir disoproxil fumarate to tenofovir alafenamide-based therapies in a Sydney HIV clinic
The transition of clinical trial data to changes in routine clinical practice is often a slow process. We describe a rapid transition of patients from one form of antiviral therapy to a modified and potentially safer version that can occur quickly when there are no financial or organisational restrictions on the prescribers.
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2011, pp.1–166, www.aidsinfo.nih.gov/Content Files/AdultandAdolescentGL.pdf (2011, accessed 8 February 2018).
2.
WoodwardCHallAWilliamsIet al.
Tenofovir-associated renal and bone toxicity. HIV Med2009;
10: 482–487.
3.
The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2017. Sydney, Australia: The Kirby Institute, UNSW Sydney.
4.
MillsAArribasJRAndrade-VillanuevaJet al.
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis2016;
16: 43–52.
5.
SaxPEWohlDYinMTet al.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet2015;
385: 2606–2615.
6.
BamRAYantSRCihlarTet al.
Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther2014;
19: 687–692.
